Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Prognostic Value of Chromosome 7 Polysomy in Non-small Cell Lung Cancer Patients Treated with Gefitinib

The Prognostic Value of Chromosome 7 Polysomy in Non-small Cell Lung Cancer Patients Treated with... ORIGINAL ARTICLE The Prognostic Value of Chromosome 7 Polysomy in Non-small Cell Lung Cancer Patients Treated with Gefitinib Lela E. Buckingham, PhD,* John S. Coon, MD, PhD,* Larry E. Morrison, PhD,† Kristine K. B. Jacobson, MSc,† Susan S. Jewell, PhD,† Kelly A. Kaiser, BSc,* Ann M. Mauer, MD,‡ Tariq Muzzafar, MD,‡ Clayton Polowy, MD,* Sanjib Basu, PhD,* Meryl Gale, MSc,* Victoria M. Villaflor, MD,* and Philip Bonomi, MD* with EGFR tyrosine kinase inhibitors is warranted in developing a Introduction: Specific subpopulations of non-small cell lung cancer clinical test for selecting patients for gefitinib therapy. (NSCLC) patients defined by clinical features and molecular profiles Key Words: Non-small cell, Targeted therapy, Molecular biomar- seem to derive greater benefit from epidermal growth factor receptor kers, Aneusomy, EGFR mutations. (EGFR) tyrosine kinase inhibitors, but no general consensus on molecular testing to optimize treatment has emerged. The objective (J Thorac Oncol. 2007;2: 414–422) of this study was to evaluate chromosome 7 polysomy and other potential indicators of gefitinib efficacy in advanced NSCLC pa- tients. n phase II trials, gefitinib (Iressa, AstraZeneca), a small Methods: Paraffin-embedded tumors from 82 patients treated with Imolecular tyrosine kinase inhibitor (TKI), demonstrated gefitinib were analyzed by immunohistochemistry for expression http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

The Prognostic Value of Chromosome 7 Polysomy in Non-small Cell Lung Cancer Patients Treated with Gefitinib

Journal of Thoracic Oncology , Volume 2 (5) – May 1, 2007

Loading next page...
 
/lp/wolters-kluwer-health/the-prognostic-value-of-chromosome-7-polysomy-in-non-small-cell-lung-buQT5kg3dP

References (33)

ISSN
1556-0864
DOI
10.1097/01.JTO.0000268675.02744.b0
pmid
17473657
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE The Prognostic Value of Chromosome 7 Polysomy in Non-small Cell Lung Cancer Patients Treated with Gefitinib Lela E. Buckingham, PhD,* John S. Coon, MD, PhD,* Larry E. Morrison, PhD,† Kristine K. B. Jacobson, MSc,† Susan S. Jewell, PhD,† Kelly A. Kaiser, BSc,* Ann M. Mauer, MD,‡ Tariq Muzzafar, MD,‡ Clayton Polowy, MD,* Sanjib Basu, PhD,* Meryl Gale, MSc,* Victoria M. Villaflor, MD,* and Philip Bonomi, MD* with EGFR tyrosine kinase inhibitors is warranted in developing a Introduction: Specific subpopulations of non-small cell lung cancer clinical test for selecting patients for gefitinib therapy. (NSCLC) patients defined by clinical features and molecular profiles Key Words: Non-small cell, Targeted therapy, Molecular biomar- seem to derive greater benefit from epidermal growth factor receptor kers, Aneusomy, EGFR mutations. (EGFR) tyrosine kinase inhibitors, but no general consensus on molecular testing to optimize treatment has emerged. The objective (J Thorac Oncol. 2007;2: 414–422) of this study was to evaluate chromosome 7 polysomy and other potential indicators of gefitinib efficacy in advanced NSCLC pa- tients. n phase II trials, gefitinib (Iressa, AstraZeneca), a small Methods: Paraffin-embedded tumors from 82 patients treated with Imolecular tyrosine kinase inhibitor (TKI), demonstrated gefitinib were analyzed by immunohistochemistry for expression

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: May 1, 2007

There are no references for this article.